Magenta Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.681
- Today's High:
- $0.7589
- Open Price:
- $0.7085
- 52W Low:
- $0.32
- 52W High:
- $1.92
- Prev. Close:
- $0.7583
- Volume:
- 376059
Company Statistics
- Market Cap.:
- $45.14 million
- Book Value:
- 1.236
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -28.85%
- Return on Equity TTM:
- -65.34%
Company Profile
Magenta Therapeutics Inc had its IPO on 2018-06-21 under the ticker symbol MGTA.
The company operates in the Healthcare sector and Biotechnology industry. Magenta Therapeutics Inc has a staff strength of 67 employees.
Stock update
Shares of Magenta Therapeutics Inc opened at $0.71 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.68 - $0.76, and closed at $0.7.
This is a -7.74% slip from the previous day's closing price.
A total volume of 376,059 shares were traded at the close of the day’s session.
In the last one week, shares of Magenta Therapeutics Inc have slipped by -6.72%.
Magenta Therapeutics Inc's Key Ratios
Magenta Therapeutics Inc has a market cap of $45.14 million, indicating a price to book ratio of 0.5371 and a price to sales ratio of 0.
In the last 12-months Magenta Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-57211000. The EBITDA ratio measures Magenta Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Magenta Therapeutics Inc’s operating margin was 0% while its return on assets stood at -28.85% with a return of equity of -65.34%.
In Q2, Magenta Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Magenta Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.11 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Magenta Therapeutics Inc’s profitability.
Magenta Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3993. Its price to sales ratio in the trailing 12-months stood at 0.
Magenta Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $78.64 million
- Total Liabilities
- $4.03 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Magenta Therapeutics Inc ended 2024 with $78.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $78.64 million while shareholder equity stood at $74.60 million.
Magenta Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.03 million in other current liabilities, 61000.00 in common stock, $-434483000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $62.63 million and cash and short-term investments were $77.59 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Magenta Therapeutics Inc’s total current assets stands at $78.64 million while long-term investments were $0 and short-term investments were $14.96 million. Its net receivables were $0 compared to accounts payable of $813000.00 and inventory worth $0.
In 2024, Magenta Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Magenta Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.7
- 52-Week High
- $1.92
- 52-Week Low
- $0.32
- Analyst Target Price
- $1
Magenta Therapeutics Inc stock is currently trading at $0.7 per share. It touched a 52-week high of $1.92 and a 52-week low of $1.92. Analysts tracking the stock have a 12-month average target price of $1.
Its 50-day moving average was $0.78 and 200-day moving average was $0.75 The short ratio stood at 1.38 indicating a short percent outstanding of 0%.
Around 222.7% of the company’s stock are held by insiders while 6263.9% are held by institutions.
Frequently Asked Questions About Magenta Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company’s product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.